Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.
Moody TW, Nuche-Berenguer B, Jensen RT.
Curr Opin Endocrinol Diabetes Obes. 2016 Feb;23(1):38-47. doi: 10.1097/MED.0000000000000218.
Vasoactive Intestinal Peptide-Secreting Tumors: A Review.
Siddappa PK, Vege SS.
Pancreas. 2019 Oct;48(9):1119-1125. doi: 10.1097/MPA.0000000000001402.
Vasoactive intestinal peptide blockade suppresses tumor growth by regulating macrophage polarization and function in CT26 tumor-bearing mice.
Kittikulsuth W, Nakano D, Kitada K, Uyama T, Ueda N, Asano E, Okano K, Matsuda Y, Nishiyama A.
Sci Rep. 2023 Jan 17;13(1):927. doi: 10.1038/s41598-023-28073-6.
[Vasoactive intestinal peptide-producing tumor (ViPoma)].
Doi R, Tsukada T.
Nihon Rinsho. 2006 Sep 28;Suppl 3:358-62.
Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma.
Ravindranathan S, Passang T, Li JM, Wang S, Dhamsania R, Ware MB, Zaidi MY, Zhu J, Cardenas M, Liu Y, Gumber S, Robinson B, Sen-Majumdar A, Zhang H, Chandrakasan S, Kissick H, Frey AB, Thomas SN, El-Rayes BF, Lesinski GB, Waller EK.
Nat Commun. 2022 Oct 27;13(1):6418. doi: 10.1038/s41467-022-34242-4.
Increased Vasoactive Intestinal Peptide (VIP) in polycystic ovary syndrome patients undergoing IVF.
Sallicandro L, Gliozheni E, Feudi D, Sabbatini P, Pellegrino RM, Alabed HBR, Baldini D, Gerli S, Alviggi C, Cascardi E, Cicinelli E, Malvasi A, Fioretti B.
Front Endocrinol (Lausanne). 2024 May 7;15:1331282. doi: 10.3389/fendo.2024.1331282. eCollection 2024.
Heparin Oligosaccharides as Vasoactive Intestinal Peptide Inhibitors via their Binding Process Characterization.
Li M, Xue Y, Chi L, Jin L.
Curr Protein Pept Sci. 2024;25(6):480-491. doi: 10.2174/0113892037287189240122110819.
Vasoactive Intestinal Peptide (VIP) Nanoparticles for Diagnostics and for Controlled and Targeted Drug Delivery.
Klippstein R, Pozo D.
Adv Protein Chem Struct Biol. 2015;98:145-68. doi: 10.1016/bs.apcsb.2014.11.006. Epub 2015 Mar 3.
Vasoactive intestinal peptide increases apoptosis of hepatocellular carcinoma by inhibiting the cAMP/Bcl-xL pathway.
Hara M, Takeba Y, Iiri T, Ohta Y, Ootaki M, Watanabe M, Watanabe D, Koizumi S, Otsubo T, Matsumoto N.
Cancer Sci. 2019 Jan;110(1):235-244. doi: 10.1111/cas.13861. Epub 2018 Dec 4.
Carcinoid heart findings in vasoactive intestinal peptide-secreting tumour.
Joshi M, Aldea D, Ngo P, Shah S.
BMJ Case Rep. 2024 Nov 7;17(11):e262229. doi: 10.1136/bcr-2024-262229.
